Print

Combination treatment for metastatic castration-resistant prostate cancer may be especially effective for people with BRCA1 or BRCA2 mutations

https://www.facingourrisk.org/XRAY/Talzenna-for-metastatic-prostate-cancer-and-HRR-mutations
Full article: https://d.docs.live.net/6e518db77f2666eb/Documents/FORCE/Fizazi et al 1-s2.0-S014067362500683X-main.pdf

This review summarizes the results of the TALAPRO2 study. It looked at how well the PARP inhibitor Talzenna (talazoparib) works for treating metastatic castration-resistant prostate cancer (mCRPC). Talzenna appears to be most effective for people with BRCA1 or BRCA2 mutations but is also effective for people with certain other mutations. (posted 9/30/25)

Questions To Ask Your Health Care Provider

I have mCRPC:

Open Clinical Trials

The following treatment studies are enrolling people with advanced prostate cancer: 

The following studies are enrolling people with advanced solid tumors, including prostate cancer: 

Other clinical trials for people with prostate cancer can be found here.

 

 


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.